09/15/2026
Before anything else, I want to acknowledge that a person lost his life. Regardless of the circumstances surrounding this case, that is incredibly sad, and my thoughts are with his family and the people who loved him.
Cases like this are also one of the reasons I have always been very cautious about medical tourism.
To be clear: I do not believe that being treated outside of the United States automatically means receiving inferior medical care. There are incredibly talented physicians and medical providers all over the world, and in some cases their experience may equal or exceed that of providers here.
The problem is often vetting.
When patients travel internationally for elective procedures, it can be much harder to determine who is truly experienced, what safety protocols are being followed, what regulatory oversight exists, and what happens if something goes wrong after you return home.
There can also be a very different dynamic when clinics primarily treat medical tourists. American and European patients can represent significant revenue, and unfortunately that can create an incentive for some providers to push beyond reasonable treatment limits in order to satisfy a patient’s request, increase the procedure size, or maximize the transaction.
Good medicine cannot work that way.
Patient satisfaction matters, but safety has to come first, even when that means telling a patient no.
Now, regarding this particular case:
Based on the limited information publicly available, my concern would be an intravascular filler event resulting in embolization. For filler to enter the circulation in a clinically significant amount, the product would have to gain vascular access. Technique, instrument selection, tissue plane, injection pressure and anatomy can all matter when evaluating how an event like that could occur.
A lot of the conversation online has focused on the reported 40 mL of filler and reduced the explanation to, “He died because they injected too much.”
I think that is an oversimplification.
